Chronic obstructive pulmonary disease includes chronic bronchitis, in which the bronchi (large air passages) are inflamed and scarred, and emphysema, in which the alveoli (tiny air sacs) are damaged. Chronic obstructive pulmonary disease (COPD) presents itself with mild, moderate, and severe symptoms. Treatment of chronic obstructive pulmonary disease (COPD) involves stepwise non-pharmacological and pharmacological interventions. Non-pharmacological interventions include risk reduction (smoking cessation) and preventing and treating co-morbidities (cardiovascular disease, anxiety, depression, and others). Pharmacological interventions include prescribing short acting bronchodilators, long acting bronchodilators, and others.
Global chronic obstructive pulmonary disease (COPD) treatment market is estimated to be valued at US$ 17,510.15 million in 2022 and is expected to exhibit a CAGR of 4.9% during the forecast period (2022-2030).
Figure 1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), by Distribution Channel, 2022
-treatment-market-figure-1.png "Chronic Obstructive Pulmonary Disease | CMI")
High incidence and prevalence of chronic obstructive pulmonary disease (COPD), coupled with awareness efforts carried out by individual organizations is expected to drive the global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period.
Increasing prevalence of chronic obstructive pulmonary disease is expected to drive the global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period. For instance, according to data published by the National Center for Biotechnology information, in 2019, 212.3 million prevalent cases of chronic obstructive pulmonary disease (COPD) were reported globally, with chronic obstructive pulmonary disease (COPD) accounting for 3.3 million deaths and 74.4 million Disability-adjusted life years. According to American Lung Association, in 2018, 9.0 million adults, or 3.6% of those aged 18 or older, had chronic bronchitis. In 2018, 16.4 million people, or 6.6% of adults, reported a diagnosis of any type of COPD (chronic bronchitis, emphysema, or COPD).
Furthermore, in November 2021, according to the data published by the National Heart, Lung and Blood Institute, each November, the chronic obstructive pulmonary disease (COPD) community comes together to promote better understanding of chronic obstructive pulmonary disease (COPD), a progressive lung disease that affects millions across the US. Increasing awareness about chronic obstructive pulmonary disease (COPD) and its symptoms is important because early diagnosis and treatment can improve quality of life.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 17,510.15 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 4.9% | 2030 Value Projection: | US$ 25,601.45 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), by Region, 2022
-treatment-market-figure-2.png "Chronic Obstructive Pulmonary Disease | CMI")
Ongoing research and development and product launches for treatment of chronic obstructive pulmonary disease are expected to drive the global chronic obstructive pulmonary disease (COPD) treatment market growth.
Increasing research and development activities by key players in market for the development of awareness and product launches is expected to drive the global chronic obstructive pulmonary disease treatment market growth. For instance, Verona Pharma, a pharmaceutical company, in May 2019, commenced a phase IIb clinical trial to assess nebulized ensifentrine (RPL554), in combination with a long-acting bronchodilator to treat moderate to severe chronic obstructive pulmonary disease.
Furthermore, in March 2019, Novartis AG, a pharmaceutical company, launched Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of chronic obstructive pulmonary disease (COPD).
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a positive impact on the global chronic obstructive pulmonary disease (COPD) treatment market, owing to the increasing demand of drugs used in the treatment of chronic obstructive pulmonary disease in patients infected with COVID-19 infection. For instance, according to an article published by the National Center for Biotechnology Information, providing access to biomedical and genomic information, in February 2022, chronic respiratory diseases (CRDs) affect the airways and other structures of the lungs, same dysfunction in lungs is observed in the patients infected with the coronavirus. The patients that are infected with coronavirus basically suffer from similar symptoms like breathing difficulty, insufficient supply of oxygen rich blood to lungs and overall body as in chronic obstructive pulmonary disease. Demand for drugs used in the treatment of chronic obstructive pulmonary disease increased as earlier in first wave of COVID-19 there was no particular drug therapy for treatment of COVID-19. The drugs used in treatment of chronic obstructive pulmonary disease were initially used in the treatment of coronavirus. It is relevant to aim for a multidisciplinary and multilevel system of care that empowers telemedicine and integrates specific psychological support programs for chronic obstructive pulmonary disease (COPD) patients and their caregivers. The SARS-CoV-2 virus causes the illness COVID-19, which may lead to mild to severe respiratory problems. These symptoms may mean people with chronic obstructive pulmonary disease (COPD) have a higher risk of more severe illness from COVID-19 due to their existing lung problems. The overall case fatality rate (CFR) was 2.3%, which means there were 1,023 deaths in 44,672 confirmed cases of COVID-19. In people with chronic respiratory disease, the CFR was 6.3%. People with severe chronic obstructive pulmonary disease (COPD) may have a higher risk of COVID-19 complications as COVID-19 affects the respiratory system. Existing lung damage means it is more difficult for the lungs to fight off an infection. Persons with chronic obstructive pulmonary disease (COPD) should not stop taking their treatments, including corticosteroids, according to the Centers for Disease Control and Prevention (CDC).
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Key Developments
In June 2022, Verona Pharma, a pharmaceutical company, announced completion of the patient enrolment, with more than 800 subjects involved for its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. It is a critical step for the phase III ENHANCE trial with top-line data expected by the end of the year 2022 and further data from ENHANCE-2 in the third quarter of 2022.
In May 2022, Alembic Pharmaceuticals Ltd, a pharmaceutical company, received final approval from the U.S. health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the U.S. Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Restraint
The major factors that hinder growth of the global chronic obstructive pulmonary disease (COPD) treatment market include that the development of new drugs is a challenging task and drug failures (termination) in clinical trials. For instance, asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, in May 2019. The Phase III, randomized, double-blind, placebo-controlled, parallel-group clinical trials GALATHEA and TERRANOVA evaluated the efficacy and safety of benralizumab for the prevention of exacerbations in patients with moderate to very severe COPD.
Furthermore, side effect of the drugs used in treating chronic obstructive pulmonary disease, is expected to hamper growth of market over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information, there are some serve side effects associated with the drugs used in the treatment of the chronic obstructive pulmonary disease, namely bruising, oral infections, and hoarseness. These medications are useful for people with frequent exacerbations of Chronic Obstructive Pulmonary Disease. Examples of inhaled steroids include, Fluticasone (Flovent HFA). Respiratory infections are observed in people with COPD who are more likely to catch colds, flu and pneumonia. Chronic Obstructive Pulmonary Disease can cause many complications like high blood pressure in lung arteries, depression, heart problems, and lung cancer in some cases.
Key Players
Major players operating in the global chronic obstructive pulmonary disease (COPD) treatment market include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA
Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic disease and its symptoms include difficulty in breathing, mucus formation, wheezing, and others. COPD is a progressive lung disease, which includes chronic bronchitis, emphysema, and refractory asthma. Prime causes behind occurrence of chronic obstructive pulmonary disease include smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (rare form of COPD), and others. There are certain ways, by which complications can be prevented, as well as disease progression can be slowed down. These may include quitting smoking, adherence to the prescribed medication, and preventing associated co-morbidities such as flu, pneumonia, and others by vaccination against these diseases. The two primary types of COPD are emphysema and chronic bronchitis. The four stages of chronic obstructive pulmonary disease (COPD) range from mild to very severe. Some symptoms may include an ongoing cough, shortness of breath, and wheezing. Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus (sputum) production and wheezing. It is typically caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. Chronic bronchitis is inflammation of the lining of the bronchial tubes, which carry air to and from the air sacs (alveoli) of the lungs. It is characterized by daily cough and mucus (sputum) production.
Market Dynamics
Key players in market are involved in improving overall chronic obstructive pulmonary disease (COPD) treatment paradigm by introducing medical devices, web-based applications, and other efforts to reduce the global burden of chronic obstructive pulmonary disease, which is expected to drive the market growth over the forecast period. For instance, in May 2019, Spire Health, a healthcare company launched a study to develop new digital biomarkers that can predict exacerbations and potentially hospitalizations in patients with severe Chronic Obstructive Pulmonary Disease.
Factors such as awareness initiatives by organizations, increasing prevalence of COPD, and product launches are driving the global chronic obstructive pulmonary disease (COPD) treatment market growth. For instance, in May 2019, Boehringer Ingelheim and Optimum Patient Care announced the creation of a new patient registry, APEX COPD, to better understand COPD and how it can be typically treated in primary care offices. Such initiatives by market players are expected to boost the global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period. Moreover, pipeline for respiratory diseases and mainly COPD has several potential medications, which is expected to drive global chronic obstructive pulmonary disease (COPD) treatment market growth.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients